The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: Thanks. Thanks, Eric. I just want to remind folks, there's three ways to ask the question, right? So you can raise your hand, which is the old school
way. And I'll call, and you can shoot me an e-mail and ask on your behalf or you can send it in the question portal, and I'll ask on your behalf as well.
But maybe I'll just start out. Eric, what are your expectations? Or how are you thinking about your base case scenario around the REMS you're
supposed to get an update in August, right?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 14, 2025 / 4:15PM, TVTX.OQ - Travere Therapeutics Inc at JPMorgan Healthcare Conference
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: So how are you thinking about -- how should we think about that?
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: So quarterly and year one basically?
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: We have an e-mail question here, which is, competitively, what are your thoughts on the potential of sparsentan to get approval without REMS?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 14, 2025 / 4:15PM, TVTX.OQ - Travere Therapeutics Inc at JPMorgan Healthcare Conference
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: Another e-mail question that we have is, what are your views on potential for sparsentan and IgAN in a post biologics world? Do you think payers
will be able to reimburse a combo?
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: Questions from the audience, PG.
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: Questions from the audience? We've got another. Yes, Malcolm.
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: We have another e-mail question here. It's on FSGS. There are competitors out there who continue to look at eGFR despite its heterogeneity as an
endpoint. Are there -- basically, are there trial design ways to maybe show an eGFR impact?
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: Questions from the audience.
Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst
: All right. Any final questions? Thanks, Eric.
| 
